Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Ampio Pharmaceuticals, Inc is a biotechnology business based in the US. Ampio Pharmaceuticals shares (AMPE) are listed on the NYSE and all prices are listed in US Dollars. Ampio Pharmaceuticals employs 23 staff and has a market cap (total outstanding shares value) of USD$144.9 million.
|Latest market close||USD$1.07|
|52-week range||USD$0.26 - USD$1.24|
|50-day moving average||USD$0.8447|
|200-day moving average||USD$0.7076|
|Wall St. target price||USD$4.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.014|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||22.99%|
|1 month (2020-11-05)||21.59%|
|3 months (2020-09-04)||50.70%|
|6 months (2020-06-05)||105.77%|
|1 year (2019-12-05)||149.71%|
|2 years (2018-12-04)||64.59%|
|3 years (2017-12-05)||-37.79%|
|5 years (2015-12-04)||-68.71%|
Valuing Ampio Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ampio Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ampio Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, Ampio Pharmaceuticals shares trade at around 27x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
|Gross profit TTM||USD$0|
|Return on assets TTM||-79.92%|
|Return on equity TTM||-185.05%|
|Market capitalisation||USD$144.9 million|
TTM: trailing 12 months
There are currently 17.9 million Ampio Pharmaceuticals shares held short by investors – that's known as Ampio Pharmaceuticals's "short interest". This figure is 12.6% up from 15.9 million last month.
There are a few different ways that this level of interest in shorting Ampio Pharmaceuticals shares can be evaluated.
Ampio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ampio Pharmaceuticals shares currently shorted divided by the average quantity of Ampio Pharmaceuticals shares traded daily (recently around 5.7 million). Ampio Pharmaceuticals's SIR currently stands at 3.13. In other words for every 100,000 Ampio Pharmaceuticals shares traded daily on the market, roughly 3130 shares are currently held short.
However Ampio Pharmaceuticals's short interest can also be evaluated against the total number of Ampio Pharmaceuticals shares, or, against the total number of tradable Ampio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ampio Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Ampio Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1027% of the tradable shares (for every 100,000 tradable Ampio Pharmaceuticals shares, roughly 103 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ampio Pharmaceuticals.
Find out more about how you can short Ampio Pharmaceuticals stock.
We're not expecting Ampio Pharmaceuticals to pay a dividend over the next 12 months.
Ampio Pharmaceuticals's shares were split on a 1:3 basis on 1 August 2008. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ampio Pharmaceuticals shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Ampio Pharmaceuticals shares which in turn could have impacted Ampio Pharmaceuticals's share price.
Over the last 12 months, Ampio Pharmaceuticals's shares have ranged in value from as little as $0.26 up to $1.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Ampio Pharmaceuticals's is 1.7534. This would suggest that Ampio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.